The safety and pharmacokinetics of rapid iloprost aerosol delivery via the BREELIB nebulizer in pulmonary arterial hypertension-Reference-Cited by-同舟云学术

The safety and pharmacokinetics of rapid iloprost aerosol delivery via the BREELIB nebulizer in pulmonary arterial hypertension

Published:2017-04 Issue:2 Volume:7 Page:505-513
ISSN:2045-8940
Container-title:Pulmonary Circulation
language:en
Short-container-title:Pulm. circ.

Author:

Gessler Tobias¹,Ghofrani Hossein‐Ardeschir¹²,Held Matthias³,Klose Hans⁴,Leuchte Hanno⁵,Olschewski Horst⁶,Rosenkranz Stephan⁷,Fels Lueder⁸,Li Na⁹,Ren Dawn⁹,Kaiser Andreas⁸,Schultze‐Mosgau Marcus‐Hillert⁸,Müllinger Bernhard¹⁰,Rohde Beate⁸,Seeger Werner¹

Affiliation:

1. Department of Internal Medicine IIUniversity of Giessen and Marburg Lung Center and Member of the German Center of Lung ResearchGiessenGermany

2. Department of MedicineImperial College LondonLondonUK

3. Respiratory Medicine and Cardiology SectionDepartment of Internal MedicineCenter for Pulmonary Hypertension and Pulmonary Vascular DiseaseMission Medical HospitalWürzburgGermany

4. Department of PneumologyUniversity Hospital Hamburg‐EppendorfHamburgGermany

5. Department of Internal Medicine IINeuwittelsbach Academic HospitalLudwig Maximilians UniversityMunichGermany

6. Division of PulmonologyMedical University of GrazGrazAustria

7. Department III of Internal Medicine and Cologne Cardiovascular Research CenterCologne University Heart CentreCologneGermany

8. Bayer AGBerlinGermany

9. Bayer HealthCare Company LtdBeijingChina

10. Vectura GmbHGautingGermany

Funder

Bayer

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1177/2045893217706691

Reference28 articles.

1. Bayer Pharma AG. Ventavis10 SmPC. Available at:http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Product_Information/human/000474/WC500048691.pdf(2016 accessed on 19 April 2016).

2. Actelion Pharma Ltd. Ventavis Prescribing information. Available at:http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021779s008lbl.pdf(2015 accessed on 13 July 2015).

3. Mechanisms of disease: pulmonary arterial hypertension;Schermuly RT;Nat Rev Cardiol,2011

4. Pulmonary arterial hypertension;Montani D;Orphanet J Rare Dis,2013

5. PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in PAH;Galiè N;Eur Respir J,2015

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Perioperative Management of Pulmonary Hypertension During Cardiac Surgery: A Call for Interdisciplinary Networking;Journal of Cardiothoracic and Vascular Anesthesia;2022-06

2. Inhaled Medicines: Past, Present, and Future;Pharmacological Reviews;2022-01

3. Digital Tracking of Physical Activity, Heart Rate, and Inhalation Behavior in Patients With Pulmonary Arterial Hypertension Treated With Inhaled Iloprost: Observational Study (VENTASTEP);Journal of Medical Internet Research;2021-10-08

4. Digital Tracking of Physical Activity, Heart Rate, and Inhalation Behavior in Patients With Pulmonary Arterial Hypertension Treated With Inhaled Iloprost: Observational Study (VENTASTEP) (Preprint);2020-11-04

5. A Case Report of a Patient With Pulmonary Arterial Hypertension Transitioned From Inhaled Iloprost to Selexipag;Journal of Pharmacy Practice;2020-09-10